DELANEY MARK E 4

What Happened

• Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics (DGX), was issued a 5,682-share performance stock award on 2026-03-04 at a reported per-share value of $204.86 (total value $1,164,015).
• Simultaneously, 2,326 shares were surrendered to the issuer to satisfy tax withholding obligations at the same per-share value (proceeds/value $476,504). This was an award settlement, not an open-market sale.
• Net shares retained from the award: 3,356 shares, with a net value of about $687,511 based on the reported price.

Key Details

• Transaction date: 2026-03-04; Form 4 filed 2026-03-06 (no late filing indicated).
• Reported price used for both issuance and withholding: $204.86 per share.
• Award type and tax action: A = Award/Grant (performance stock award); F = disposition to cover tax withholding.
• Footnotes: (1) Stock issued in settlement of a performance stock award under Rule 16b‑3(d). (2) Shares were surrendered solely to cover tax withholding obligations.
• Shares owned after the transaction: Not specified in the filing.

Context

• This filing reflects the settlement of a performance-based equity award (typical executive compensation), with a portion withheld for taxes — a common administrative action that does not indicate an open-market sale.
• For retail investors, awards increase insider ownership but withholding is routine and does not imply a change in bullish/bearish stance.